Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquired |
gptkb:Novartis
|
| gptkbp:acquisition |
gptkb:2020
|
| gptkbp:ceo |
gptkb:Claudio_Albrecht
|
| gptkbp:focus |
innovative medicines
|
| gptkbp:founded |
gptkb:1996
|
| gptkbp:headquarters |
gptkb:Parsippany-Troy_Hills,_New_Jersey
|
| https://www.w3.org/2000/01/rdf-schema#label |
The Medicines Company
|
| gptkbp:industry |
gptkb:Company
|
| gptkbp:key_people |
David A. Kallend
|
| gptkbp:location |
gptkb:United_States
|
| gptkbp:notable_products |
gptkb:Inclisiran
gptkb:Angiomax |
| gptkbp:research_areas |
cardiovascular diseases
|
| gptkbp:revenue |
$100 million (2019)
|
| gptkbp:services |
clinical development
|
| gptkbp:subsidiary |
gptkb:The_Medicines_Company_(Ireland)_Limited
|
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:type |
gptkb:Company
|
| gptkbp:website |
www.themedicinescompany.com
|
| gptkbp:bfsParent |
gptkb:Novartis_AG
gptkb:Novartis_Group |
| gptkbp:bfsLayer |
5
|